Cancer Discovery

Scientists build a new model of CAR-T cells — Ones with Powerful “Armor” that allow them to fight Solid Tumors

Engineered T-cell therapy, and in particular CAR T-cells, have shown efficacy in CD-19+ blood cancer such as lymphomas and leukemias. However, to date, T-cell therapies have found little success in solid tumors – in part due to the immunosuppressive tumor microenvironment. Checkpoint inhibitors, on the other hand, have been proven effective at empowering the immune […]

cancer Immunotherapies

First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. The approach is the first to use chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR). […]

Biotechnology cancer Cell Therapy

FDA Approves CAR T Therapy for Large B-Cell Lymphoma Developed at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. Today’s approval includes treatment of diffuse large B-cell […]

Biotechnology Clinical Trials Gene Therapy Uncategorized

CAR T-Cell Therapy for Leukemia Leads to Remissions in Clinical Trial

In an early-phase clinical trial of an experimental immunotherapy, researchers achieved durable molecular remissions in patients with chronic lymphocytic leukemia who had failed other treatments Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric antigen […]

cancer Clinical Trials Immunotherapies

Experimental CAR-T Treatment Halted as Two More Patients Die During Clinical Trials

Juno Therapeutics said Wednesday it has suspended a Phase II clinical trial of a cancer drug after two patients suffered cerebral edema earlier this week, leaving one dead and the other not expected to recover. The company’s ‘Rocket’ trial for B cell acute lymphoblastic leukemia is testing a drug it calls JCAR015. These drugs work […]

Cell Therapy Pharmaceutical Business News

Novartis Dissolves Its Cell Therapy Unit; 120 Positions Eliminated

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment. Cell and gene therapy development will no longer be housed in a separate division, the Basel, Switzerland-based company said […]

Biotechnology Pharmaceutical Business News Pharmaceuticals

Q&A with Denis Corin, Q Bio Med Inc – Getting Past the “Pharma Bro” – Smaller Biotech Continue to Strive for Well-Being of Patients

There has been a vast amount of mixed feelings surrounding the biotech/drug company development of drugs and the final price consumers/patients are paying. Especially when one biotech CEO, Martin Shkreli (aka ‘Pharma Bro”) decided to massively increase of a very cheap drug vital to patients with HIV from $13.50 to $750. The actions of one CEO […]